Search results
Results from the WOW.Com Content Network
How a new FDA-approved drug can — and can’t — help people with Alzheimer’s December 25, 2024 at 10:08 AM If you have a loved one with Alzheimer’s disease, you may have read about a newly ...
An Alzheimer’s disease drug may soon have a new dosing schedule. The medication, Leqembi, is currently administered via an infusion every two weeks. Under the proposed changes, the medication ...
Lecanemab (a.k.a. leqembi) has received full approval from the U.S. Food and Drug Administration. This is the first FDA-approved treatment to help slow the progression of Alzheimer’s disease.
The Alzheimer's drug Leqembi. (Eisai/Handout via Reuters) (Handout . / reuters) Around 25% of the population has one copy of the APOE4 gene, while up to 3% have two copies of the gene, according ...
After a lull of nearly 2 decades, the Food and Drug Administration (FDA) has approved some novel drugs for the treatment of Alzheimer’s disease since 2021.
Crenezumab was developed by Ruth Greferath, Ph.D., and Claude Nicolau, Ph.D., before the Swiss-based biopharmaceutical company AC Immune was founded, which focuses on developing targeted therapeutics for misfolded proteins that cause neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. [4]
The medication has shown some promise at addressing what may be an underlying cause of the disease, but its ability to slow or reverse cognitive decline remains unproven.
The FDA had proposed that companies testing new anti-amyloid drugs exclude any volunteer from clinical trials who had more than two brain microbleeds, according to an Alzheimer's Assn. report.